Biomarcadores clínicos de sintomas não motores na doença de Parkinson
DOI:
https://doi.org/10.34024/rnc.2021.v29.11788Palavras-chave:
Biomarcador, Doença de Parkinson, Avaliação de SintomasResumo
Introdução. A doença de Parkinson (DP) é o segundo distúrbio neurodegenerativo que mais afeta a população idosa acima de 60 anos. Os sintomas não motores desempenham um papel fundamental na trajetória da doença, assim a identificação de biomarcadores periféricos e/ou centrais que sejam sensíveis, específicos e econômicos para o diagnóstico diferencial precoce, prognóstico e tratamento da DP são fundamentais para o manejo desses pacientes. Objetivo. Identificar e discutir as características dos principais de biomarcadores clínicos de sintomas não motores na DP. Método. Trata-se de uma revisão bibliográfica através das bases dados PubMed/MEDLINE, SciELO, Science Direct. Os artigos foram selecionados segundo os critérios de inclusão: ensaios clínicos controlados randomizados, estudos quasi-experimentais e revisões sistemáticas que registraram a utilização de biomarcadores de sintomas não motores na DP. Resultados. A estratégia de busca utilizada resultou em 705 títulos, onde um total de 21 estudos foram incluídos para análise. Mais de 90% dos pacientes experimentam sintomas não motores durante o curso da DP. Os principais sintomas não motores relatados envolvem alterações do sistema sensorial, cognitivo e mudanças de personalidade. Conclusão. Os biomarcadores identificados neste estudo destacam o papel da identificação dos sintomas clínicos não motores no diagnóstico precoce da doença de Parkinson e o entendimento da etiologia para direcionar um manejo eficaz.
Downloads
Métricas
Referências
Goldman JG, Postuma R. Premotor and nonmotor features of Parkinson’s disease. Curr Opin Neurol 2014;27:434-41. https://doi.org/10.1097/WCO.0000000000000112
Sharma VD, Lyons KE, Pahwa R. Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease. Ther Clin Risk Manag 2018;14:665-73. https://doi.org/10.2147/TCRM.S144481
Wang J, Hoekstra JG, Zuo C, Cook TJ, Zhang J. Biomarkers of Parkinson’s disease: Current status and future perspectives. Drug Discov Today 2013;18:155-62. https://doi.org/10.1016/j.drudis.2012.09.001
Mahlknecht P, Seppi K, Poewe W. The concept of prodromal Parkinson’s disease. J Parkinsons Dis 2015;5:681-97. https://doi.org/10.3233/JPD-150685
Kumaresan M, Khan S. Spectrum of Non-Motor Symptoms in Parkinson’s Disease. Cureus 2021;13:e13275. https://doi.org/10.7759/cureus.13275
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and explanation. BMJ 2015;349:g7647. http://doi.org/10.1136/bmj.g7647
Delenclos M, Jones DR, McLean PJ, Uitti RJ. Biomarkers in Parkinson’s disease: Advances and strategies. Park Relat Disord 2016;22:S106-10. http://doi.org/10.1016/j.parkreldis.2015.09.048
Miller DB, O’Callaghan JP. Biomarkers of Parkinson’s disease: Present and future. Metabolism 2015;64:S40-6. http://doi.org/10.1016/j.metabol.2014.10.030.
Costa MFBNA, Reisdorfer E, Kempfer SS, Fernandes GCM, Porporatti AL, Canto GDL. Diagnostic validity of biomarkers in Parkinson’s Disease: systematic review and meta-analysis. Rev Bras Enferm 2018;71:3074-83. https://doi.org/10.1590/0034-7167-2017-0822
Siderowf A, Lang AE. Premotor Parkinson’s disease: Concepts and definitions. Mov Disord 2012;27:608-16. http://doi.org/10.1002/mds.24954
Swallow DMA, Lawton MA, Grosset KA, Malek N, Smith CR, Bajaj NP, et al. Variation in recent onset Parkinson’s disease: Implications for prodromal detection. J Parkinsons Dis 2016;6:289-300. http://doi.org/10.3233/JPD-150741
Savica R, Rocca WA, Ahlskog JE. When does Parkinson disease start? Arch Neurol 2010;67:798-801. http://doi.org/10.1001/archneurol.2010.135
Berg D, Godau J, Seppi K, Behnke S, Liepelt-Scarfone I, Lerche S, et al. The PRIPS study: Screening battery for subjects at risk for Parkinson’s disease. Eur J Neurol 2013;20:102-8. http://doi.org/10.1111/j.1468-1331.2012.03798.x
Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci 2017;18:435-50. https://doi.org/10.1038/nrn.2017.62
Lotankar S, Prabhavalkar KS, Bhatt LK. Biomarkers for Parkinson’s Disease: Recent Advancement. Neurosci Bull 2017;33:585-97. http://doi.org/10.1007/s12264-017-0183-5
Chase BA, Markopoulou K. Olfactory Dysfunction in Familial and Sporadic Parkinson’s Disease. Front Neurol 2020;11:1-11. https://doi.org/10.3389/fneur.2020.00447
Tunc S, Graf J, Tadic V, Brüggemann N, Schmidt A, Al-Khaled M, et al. A population-based study on combined markers for early Parkinson’s disease. Mov Disord 2015;30:531-7. http://doi.org/10.1002/mds.26100
López Hernández N, García Escrivá A, Shalabi Benavent M. Valor de la evaluación combinada de olfación e hiperecogenicidad de sustancia negra en el diagnóstico de la enfermedad de Parkinson. Neurología 2015;30:496-501. https://doi.org/10.1016/j.nrl.2014.03.010
He R, Zhao Y, He Y, Zhou Y, Yang J, Zhou X, et al. Olfactory Dysfunction Predicts Disease Progression in Parkinson’s Disease: A Longitudinal Study. Front Neurosci 2020;14:1-9. https://doi.org/10.3389/fnins.2020.569777
Postuma RB, Iranzo A, Hogl B, Arnulf I, Ferini-Strambi L, Manni R, et al. Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: A multicenter study. Ann Neurol 2015;77:830-9. http://doi.org/10.1002/ana.24385
Postuma RB, Gagnon JF, Bertrand JA, Génier Marchand D, Montplaisir JY. Parkinson risk in idiopathic REM sleep behavior disorder: Preparing for neuroprotective trials. Neurology 2015;84:1104-13. http://doi.org/10.1212/WNL.0000000000001364
Postuma RB. Prodromal Parkinson’s disease - Using REM sleep behavior disorder as a window. Park Relat Disord 2014;20(suppl 1):S1–4. https://doi.org/10.1016/S1353-8020(13)00400-8
Sharma S, Moon CS, Khogali A, Haidous A, Chabenne A, Ojo C, et al. Biomarkers in Parkinson’s disease (recent update). Neurochem Int 2013;63:201-29. https://doi.org/10.1016/j.neuint.2013.06.005
Skorvanek M, Feketeova E, Kurtis MM, Rusz J, Sonka K. Accuracy of rating scales and clinical measures for screening of rapid eye movement sleep behavior disorder and for predicting conversion to Parkinson’s disease and other synucleinopathies. Front Neurol 2018;9:1-18. https://doi.org/10.3389/fneur.2018.00376
Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 2001;57:456-62. http://doi.org/10.1212/wnl.57.3.456
Fayyad M, Salim S, Majbour N, Erskine D, Stoops E, Mollenhauer B, et al. Parkinson’s disease biomarkers based on α-synuclein. J Neurochem 2019;150:626-36. https://doi.org/10.1111/jnc.14809
Pouclet H, Lebouvier T, Coron E, Bruley des Varannes S, Rouaud T, Roy M, et al. A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson’s disease. Neurobiol Dis 2012;45:305-9. https://doi.org/10.1016/j.nbd.2011.08.014
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2021 Robson Arruda Souza, Ivan Victor Torres Vieira, Jairo Pereira da Silva
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Aceito: 2021-06-25
Publicado: 2021-08-19
Português
English
Español
